Back to top
more

IQVIA (IQV)

(Real Time Quote from BATS)

$225.18 USD

225.18
399,043

-4.66 (-2.03%)

Updated Oct 7, 2024 02:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Subham Roy headshot

Clarivate (CLVT) to Develop Unified Library Solution for Ohio

by Subham Roy

Clarivate (CLVT) partners with OhioLINK and SearchOhio to integrate their INN-Reach platforms to develop a unified library solution for the state of Ohio.

IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

IQVIA (IQV) delivered earnings and revenue surprises of 2.33% and 0.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

IQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.

Clinical Development Expertise Aids IQVIA (IQV), Costs High

by Zacks Equity Research

IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.

Paychex (PAYX) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Paychex's (PAYX) fourth-quarter fiscal 2024 earnings and revenues are expected to have increased year over year.

EPAM Expands in Life Sciences Space With Odysseus Buyout

by Zacks Equity Research

EPAM acquires Odysseus Data Services to enhance its life sciences value chain by leveraging the latter's expertise in analytics, data methods and artificial intelligence.

IQVIA (IQV) Announces Launch of Trial Technology Platform

by Zacks Equity Research

IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.

Here's Why You Should Hold on to IQVIA (IQV) Stock for Now

by Zacks Equity Research

IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.

What's in Store for International Money's (IMXI) Q1 Earnings?

by Zacks Equity Research

International Money's (IMXI) revenues are likely to have benefitted from technological advancements, making transactions fast for Digital and Retail customers.

Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q1

by Zacks Equity Research

IQVIA's (IQV) rise in segmental revenues results in y/y top-line growth in first-quarter 2024.

IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

IQVIA (IQV) delivered earnings and revenue surprises of 2.83% and 1.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

IQVIA (IQV) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

IQVIA Holdings' (IQV) first-quarter 2024 revenues are likely to have benefited from growth in the Technology and Analytics, and Research and Development segments.

Countdown to IQVIA (IQV) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for IQVIA (IQV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Retain IQVIA (IQV) Stock in Your Portfolio Now

by Zacks Equity Research

IQVIA (IQV) is benefitting from its robust capabilities and expansive strategy amid low liquidity and foreign currency exchange rate fluctuation risks.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IQVIA (IQV) Appreciates 24% in a Year: Here's What to Know

by Zacks Equity Research

IQVIA's (IQV) combined offerings of research and development and commercial services are helping it to develop trusted relationships.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Why Is Tandem Diabetes Care (TNDM) Up 27.4% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IQVIA (IQV) Up 5.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IQVIA (IQV) Gains From Global IT Framework, Liquidity Low

by Zacks Equity Research

IQVIA's (IQV) revenue growth is primarily driven by global IT infrastructure and market size amid increasing operating expenses and low liquidity.

Tandem Diabetes Care, Inc. (TNDM) Surges 9.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.